Central Serous Chorioretinopathy: Etiology, Course and Prognosis

Central Serous Chorioretinopathy: An Observational Study About Etiology, Course and Prognosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01378130

Enrollment

Registered

2011-06-22

Start date

2011-04-30

Completion date

2013-04-30

Last updated

2013-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Serous Chorioretinopathy

Keywords

CCS, CSC, Subretinal Fluid, multimodal imaging

Brief summary

Pathogenesis of central serous chorioretinopathy is not entirely understood yet, therefore further investigations are needed. During this study patients with an acute episode of central serous chorioretinopathy are observed with established ophthalmologic methods (multimodal imagine) every 6 weeks until subretinal fluid is reabsorbed to gain further insides in etiology, course and prognosis of this disease.

Detailed description

Patients with central serous chorioretinopathy are recruited from the Department of Ophthalmology at the Medical University of Vienna. All patients undergo ETDRS visual acuity measurement, Pelli-Robson contrast examination, Amsler-Grid testing, questionnaire testing, ophthalmologic examination, SD-OCT and polarization-sensitive OCT, fundus autofluorescence, fluorescein angiography, indocyanine-green angiography, fundus photo and microperimetry. Patients are re-examined after an interval of 6 weeks until subretinal fluid is entirely reabsorbed to gain further insides in etiology, course and prognosis of this disease.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Signed informed consent form * Age over 18 years * acute episode of Central Serous Chorioretinopathy * Symptoms for less than two weeks * no treatment on study eye

Exclusion criteria

* bad compliance * protected patient group (pregnant women)

Design outcomes

Primary

Measure	Time frame	Description
Clinical Outcome	2 years	OCT, Visus

Secondary

Measure	Time frame	Description
Subclinical Data	2 years	FA findings, retinal sensitivity in Microperimetry, contrast sensitivity, Amsler Grid Test

Countries

Austria

Outcome results